Document is current
Any future updates will be listed below
-
Authors
Hocine, Hocine R.
Ganbaatar, Undrakh
Amador-Molina, Alfredo https://orcid.org/0009-0009-6406-3565
Banerjee, Srijita
Misawa, Kyohei
Rubino, Viviana
Ankola, Pratiti
Fong, Christina https://orcid.org/0000-0001-9964-5877
Xiong, Yuquan
Vista, William-Ray https://orcid.org/0000-0001-5254-2336
Bellis, Rebecca Y.
Chintala, Navin K. https://orcid.org/0000-0003-4229-0977
Curran, Kevin J.
Sulis, Maria Luisa
Park, Jae H. https://orcid.org/0000-0002-2903-5130
Kung, Andrew L. https://orcid.org/0000-0002-9091-488X
Adusumilli, Prasad S. https://orcid.org/0000-0002-1699-2046
- License Information
-
More Information
Article History
Received: 20 August 2025
Accepted: 9 July 2026
First Online: 15 July 2026
Ethics
Competing interests: P.S.A. declares research funding from Novocure; Scientific Advisory Board Member and/or Consultant for Affyimmune Therapeutics, Bio4t2, Carisma Therapeutics, Century Therapeutics, Orion Pharma, Outpace Bio, Pluri-biotech, and Verismo Therapeutics; patents, royalties, and intellectual property on mesothelin-targeted CAR and other T-cell therapies, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has previously licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics and had associated financial interests. The remaining authors declare no competing interests.
